JP2012136529A5 - - Google Patents

Download PDF

Info

Publication number
JP2012136529A5
JP2012136529A5 JP2012030227A JP2012030227A JP2012136529A5 JP 2012136529 A5 JP2012136529 A5 JP 2012136529A5 JP 2012030227 A JP2012030227 A JP 2012030227A JP 2012030227 A JP2012030227 A JP 2012030227A JP 2012136529 A5 JP2012136529 A5 JP 2012136529A5
Authority
JP
Japan
Prior art keywords
ephrin
drug
subject
receptor antagonist
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012030227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012136529A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012136529A publication Critical patent/JP2012136529A/ja
Publication of JP2012136529A5 publication Critical patent/JP2012136529A5/ja
Withdrawn legal-status Critical Current

Links

JP2012030227A 2004-09-08 2012-02-15 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 Withdrawn JP2012136529A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2004905148A AU2004905148A0 (en) 2004-09-08 A method of treatment and agents useful for same
AU2004905148 2004-09-08
US64796805P 2005-01-27 2005-01-27
US60/647,968 2005-01-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007530543A Division JP5094395B2 (ja) 2004-09-08 2005-09-08 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置

Publications (2)

Publication Number Publication Date
JP2012136529A JP2012136529A (ja) 2012-07-19
JP2012136529A5 true JP2012136529A5 (enExample) 2012-08-30

Family

ID=36036018

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007530543A Expired - Fee Related JP5094395B2 (ja) 2004-09-08 2005-09-08 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置
JP2012030227A Withdrawn JP2012136529A (ja) 2004-09-08 2012-02-15 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007530543A Expired - Fee Related JP5094395B2 (ja) 2004-09-08 2005-09-08 Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置

Country Status (6)

Country Link
US (1) US20080254023A1 (enExample)
EP (1) EP1793854A4 (enExample)
JP (2) JP5094395B2 (enExample)
CA (1) CA2579352A1 (enExample)
NZ (1) NZ553273A (enExample)
WO (1) WO2006026820A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP674898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
WO2006026820A1 (en) * 2004-09-08 2006-03-16 The University Of Queensland Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor
AU2007272533A1 (en) * 2006-07-13 2008-01-17 Novartis Ag Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders
US8530181B2 (en) 2007-11-15 2013-09-10 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
US7892769B2 (en) * 2007-11-30 2011-02-22 Eisai R&D Management Co., Ltd. Processing of EphA4 polypeptide by γ-secretase activity
EP2260864A1 (en) * 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
WO2012081502A1 (ja) 2010-12-17 2012-06-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法
WO2012147798A1 (ja) 2011-04-25 2012-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
US10322161B2 (en) 2014-07-15 2019-06-18 Sanford Burnham Prebys Medical Discovery Institute EPHA4 cyclic peptide antagonists for neuroprotection and neural repair
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
MA56466A (fr) 2019-07-01 2022-05-11 Eisai R&D Man Co Ltd Anticorps anti-epha4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP674898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
AU2003268345A1 (en) * 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
WO2004041197A2 (en) * 2002-11-01 2004-05-21 Case Western Reserve University Methods of inhibiting glial scar formation
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
WO2006026820A1 (en) * 2004-09-08 2006-03-16 The University Of Queensland Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor

Similar Documents

Publication Publication Date Title
JP2012136529A5 (enExample)
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
JP2011006431A5 (enExample)
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
JP2012126725A5 (enExample)
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BR112015003376A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
EP2742155A4 (en) BIOMARKER FOR ALZHEIMER'S DISEASE AND / OR COGNITIVE LIGHT DISORDER, AND USE THEREOF
IL218674A (en) Compounds that inhibit lrrk2 kinase activity, pharmacological preparations containing them, and their use in the preparation of Parkinson's disease drugs
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2013014622A5 (enExample)
HUE038313T2 (hu) Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban
PT2655375E (pt) Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
IL221160A (en) 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation
HUE037742T2 (hu) Szubsztituált azolok, vírusellenes aktív adalék, gyógyszerészeti készítmény, az elõállításukat célzó eljárás és alkalmazásuk
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
CL2013001943A1 (es) Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.
IL232764A (en) Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
IL211713A0 (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
EP3157447A4 (en) Identifying a target anatomic location in a subject's body, and delivering a medicinal substance thereto
EP3162804A8 (en) New benzodiazepine derivative and use thereof